COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で69.98%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 9.59Mに達しています。
適正水準
同社の最新のは-0.42で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は331.27K株で、前四半期比で2.04%減少しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は-0.11です。